Head to head
Pacira BioSciences vs Takeda Pharmaceutical
Side-by-side on the measures that matter, with a plain-English read. Full detail: PCRX · TAK
PCRX
Pacira BioSciences
36.48+0.00%
1-year price shape — +50% over the period
Quant Rating C · 86/100
vs
TAK
Takeda Pharmaceutical
21.77+1.68%
1-year price shape — +57% over the period
Quant Rating C · 88/100
1-year performance, rebased to 100
Takeda Pharmaceutical edges it on the scoreable measures. Takeda Pharmaceutical has the highest Quant Rating (88); Takeda Pharmaceutical has done best over the past year (+57%); Takeda Pharmaceutical pays the highest dividend yield.
| PCRX | TAK | |
|---|---|---|
| Snapshot | ||
| Sector | -- | -- |
| Last price | 36.48 | 21.77 |
| Change today | +0.00% | +1.68% |
| 1-year return | +49.6% | +57.5% |
| Market cap | $1.46B | $69.76B |
| 52-week range | 18.80 – 36.67 | 13.92 – 22.07 |
| Valuation | ||
| P/E (TTM) | 39.23 | 311.00 |
| P/E percentile, own 5-yr range | 44th | 100th |
| P/B | 2.05 | 1.50 |
| Dividend yield | 0.00% | 1.44% |
| Profitability & growth | ||
| EPS (TTM) | 0.16 | -0.30 |
| Net profit (TTM) | $6.42M | $-970.94M |
| Revenue (TTM) | $743.30M | $4.69T |
| Provider revenue period date | 2026-09-29 | 2026-09-29 |
| Revenue growth (YoY) | -1.6% | +6.7% |
| Gross margin | 78.7% | 65.8% |
| Operating margin | 3.0% | 14.3% |
| Net margin | 5.1% | 0.9% |
| Free cash flow (TTM) | $169.00M | $433.95B |
| Provider cash-flow period date | 2026-09-29 | 2026-09-29 |
| Ownership & sentiment | ||
| Institutional ownership | 113.6% | 51.3% |
| Insider activity (12mo) | 23 buy / 27 sell | 19 buy / 31 sell |
| Short interest (% of float) | 8.4% | 0.1% |
| Analyst consensus | 100% hold (9) | 100% buy (1) |
| Analyst price target | $35 (-5%) | $50 (+132%) |
| StockVane view | ||
| StockVane Quant Rating | C (86) | C (88) |
| Company | ||
| Employees | 829 | 47,029 |
| Founded | 2006 | 1781 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.